Lineage Cell Therapeutics, Inc. Amortization of Debt Issuance Costs
Lineage Cell Therapeutics, Inc. (LCTX) reported Amortization of Debt Issuance Costs of $22.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2024-03-07
- Lineage Cell Therapeutics, Inc. amortization of debt issuance costs for fiscal 2023 was $22.00K.
| Period end | Amortization of Debt Issuance Costs 12 month |
|---|---|
| 2023-12-31 | $22.00K 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |